Search

Your search keyword '"Shyr, Yu"' showing total 2,014 results
Start Over Author "Shyr, Yu"
2,014 results on '"Shyr, Yu"'

201. Additional file 1 of RnaSeqSampleSize: real data based sample size estimation for RNA sequencing

Author

Zhao, Shilin, Li, Chung-I, Guo, Yan, Sheng, Quanhu, and Shyr, Yu

Subjects
natural sciences
Abstract

Table S1. The improvement in efficiency in RnaSeqSampleSize package. Table S2. Estimated sample size for RNA-Seq experiments in different cancer types by single parameter method. Table S3. Estimated sample size for RNA-Seq experiments in different cancer types by real data distribution based method. For each cancer type, we used the related TCGA dataset to estimate the read count and dispersion distribution. Table S4. Estimated sample size for RNA-Seq experiments in different cancer types by real data distribution based method, only the genes in interested KEGG pathway were considered. Table S5. Estimated sample size for RNA-Seq experiments in different cancer types by real data distribution based method, only the genes in KEGG pathway ID 05200 (Pathways in Cancer) were considered. Figure S1. A screen shot of user interface of RnaSeqSampleSize package. (DOCX 217 kb)

Published
2022
Full Text
View/download PDF

204. Power and sample sizes estimation in clinical trials with treatment switching in intention-to-treat analysis: a simulation study.

Author

Deng, Lejun, Hsu, Chih-Yuan, and Shyr, Yu

Subjects
SAMPLE size (Statistics), CLINICAL trials, TREATMENT effectiveness
Abstract

Background: Treatment switching, also called crossover, is common in clinical trials because of ethical concerns or other reasons. When it occurs and the primary objective is to identify treatment effects, the most widely used intention-to-treat analysis may lead to underpowered trials. Here, we presented an approach to preview power reductions and to estimate sample sizes required to achieve the desired power when treatment switching occurs in the intention-to-treat analysis. Methods: We proposed a simulation-based approach and developed an R package to perform power and sample sizes estimation in clinical trials with treatment switching. Results: We simulated a number of randomized trials incorporating treatment switching and investigated the impact of the relative effectiveness of the experimental treatment to the control, the switching probability, the switching time, and the deviation between the assumed and the real distributions for the survival time on power reductions and sample sizes estimation. The switching probability and the switching time are key determinants for significant power decreasing and thus sample sizes surging to maintain the desired power. The sample sizes required in randomized trials absence of treatment switching vary from around four-fifths to one-seventh of the sample sizes required in randomized trials allowing treatment switching as the switching probability increases. The power reductions and sample sizes increase with the decrease of switching time. Conclusions: The simulation-based approach not only provides a preview for power declining but also calculates the required sample size to achieve an expected power in the intention-to-treat analysis when treatment switching occurs. It will provide researchers and clinicians with useful information before randomized controlled trials are conducted. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

205. Using the HER2/CEP17 FISH Ratio to Predict Pathologic Complete Response Following Neoadjuvant Anti-HER2 Doublet Therapy in HER2+ Breast Cancer.

Author

Lander, Eric M, Rappazzo, Katherine C, Huang, Li-Ching, Hu, Jiun-Ruey, Chen, Heidi, Shyr, Yu, and Abramson, Vandana G

Subjects
BREAST cancer prognosis, THERAPEUTIC use of antineoplastic agents, BIOPSY, CONFIDENCE intervals, TRASTUZUMAB, ONCOGENES, RETROSPECTIVE studies, ACQUISITION of data, CANCER patients, PATHOLOGIC complete response, MEDICAL records, DESCRIPTIVE statistics, TUMOR markers, COMBINED modality therapy, LOGISTIC regression analysis, ODDS ratio, BREAST tumors
Abstract

Background: Clinical trials of HER2-directed therapy that omit neoadjuvant conventional chemotherapy for HER+ breast cancer demonstrate that a subset of patients still obtains a pCR. Identifying tumor characteristics which predict pCR may help select patients for de-escalated neoadjuvant dual HER2-targeted treatment without chemotherapy. This is the first study evaluating the HER2/CEP17 ratio by FISH as a biomarker to predict pCR among patients who received neoadjuvant anti-HER2 regimens without chemotherapy. Patients and Methods: Data from patients with locally advanced HER2+ breast cancer who received neoadjuvant dual HER2-targeted therapy without conventional chemotherapy from a single center was retrospectively reviewed. All patients were enrolled in one of 3 clinical trials evaluating chemotherapy de-escalation. Logistic regression modeling assessed for a relationship between the HER2/CEP17 FISH ratio obtained from baseline tissue biopsy and pCR based on pathology at the time of definitive breast surgery following neoadjuvant treatment. Results: Following neoadjuvant treatment with dual HER2-targeted therapies in 56 patients, the probability of pCR was 73% among patients with a HER2 ratio of 13.1 compared to a probability of 38% among patients with HER2 ratio of 5.5 (OR 4.14, 95% CI 1.44-11.89; P = .012). This positive association persisted after controlling for different treatment regimens administered (OR 2.87, 95% CI 0.9-9.18, P = .020). Conclusions: These data found a positive association between the HER2/CEP17 FISH ratio and pCR following neoadjuvant dual HER2-targeted therapy without chemotherapy. Larger prospective studies are needed to validate the HER2 ratio as a biomarker to select patients for neoadjuvant dual anti-HER2 therapy without chemotherapy. This novel exploratory study is the first to examine whether pathologic complete response following various neoadjuvant anti-HER2 doublet therapies without conventional chemotherapy is dependent on the level of HER2 amplification. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

209. DC isoketal-modified proteins activate T cells and promote hypertension

Author

Kirabo, Annet, Fontana, Vanessa, de Faria, Ana P.C., Loperena, Roxana, Galindo, Cristi L., Wu, Jing, Bikineyeva, Alfiya T., Dikalov, Sergey, Xiao, Liang, Chen, Wei, Saleh, Mohamed A., Trott, Daniel W., Itani, Hana A., Vinh, Antony, Amarnath, Venkataraman, Amarnath, Kalyani, Guzik, Tomasz J., Bernstein, Kenneth E., Shen, Xiao Z., Shyr, Yu, Chen, Sheau-chiann, Mernaugh, Raymond L., Laffer, Cheryl L., Elijovich, Fernando, Davies, Sean S., Moreno, L. Heitor, Madhur, Meena S., Roberts, II, Jackson, and Harrison, David G.

Subjects
T cells -- Properties, Dendritic cells -- Properties, Hypertension -- Genetic aspects -- Development and progression, Health care industry
Abstract

Oxidative damage and inflammation are both implicated in the genesis of hypertension; however, the mechanisms by which these stimuli promote hypertension are not fully understood. Here, we have described a pathway in which hypertensive stimuli promote dendritic cell (DC) activation of T cells, ultimately leading to hypertension. Using multiple murine models of hypertension, we determined that proteins oxidatively modified by highly reactive γ-ketoaldehydes (isoketals) are formed in hypertension and accumulate in DCs. Isoketal accumulation was associated with DC production of IL-6, IL-1β, and IL-23 and an increase in costimulatory proteins CD80 and CD86. These activated DCs promoted T cell, particularly [CD8.sup.+] T cell, proliferation; production of IFN-γ and IL-17A; and hypertension. Moreover, isoketal scavengers prevented these hypertension-associated events. Plasma F2-isoprostanes, which are formed in concert with isoketals, were found to be elevated in humans with treated hypertension and were markedly elevated in patients with resistant hypertension. Isoketal-modified proteins were also markedly elevated in circulating monocytes and DCs from humans with hypertension. Our data reveal that hypertension activates DCs, in large part by promoting the formation of isoketals, and suggest that reducing isoketals has potential as a treatment strategy for this disease., Introduction It is well established that inflammation is involved in the genesis of hypertension (1). T cells and macrophages accumulate in the kidneys and vasculature of animals with experimental hypertension [...]

Published
2014
Full Text
View/download PDF

210. COVID-19 vaccination and breakthrough infections in patients with cancer

Author

Schmidt, A.L., primary, Labaki, C., additional, Hsu, C.-Y., additional, Bakouny, Z., additional, Balanchivadze, N., additional, Berg, S.A., additional, Blau, S., additional, Daher, A., additional, El Zarif, T., additional, Friese, C.R., additional, Griffiths, E.A., additional, Hawley, J.E., additional, Hayes-Lattin, B., additional, Karivedu, V., additional, Latif, T., additional, Mavromatis, B.H., additional, McKay, R.R., additional, Nagaraj, G., additional, Nguyen, R.H., additional, Panagiotou, O.A., additional, Portuguese, A.J., additional, Puc, M., additional, Santos Dutra, M., additional, Schroeder, B.A., additional, Thakkar, A., additional, Wulff-Burchfield, E.M., additional, Mishra, S., additional, Farmakiotis, D., additional, Shyr, Yu, additional, Warner, J.L., additional, Choueiri, T.K., additional, Duma, N., additional, Grivas, P., additional, de Lima Lopes, G., additional, Painter, C.A., additional, Peters, S., additional, Rini, B.I., additional, Shah, D.P., additional, and Thompson, M.A., additional

Published
2022
Full Text
View/download PDF

213. Lung Cancer and Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Identifying Important Knowledge Gaps for Investigation

Author

Rolfo, Christian, primary, Meshulami, Noy, additional, Russo, Alessandro, additional, Krammer, Florian, additional, García-Sastre, Adolfo, additional, Mack, Philip C., additional, Gomez, Jorge E., additional, Bhardwaj, Nina, additional, Benyounes, Amin, additional, Sirera, Rafael, additional, Moore, Amy, additional, Rohs, Nicholas, additional, Henschke, Claudia I., additional, Yankelevitz, David, additional, King, Jennifer, additional, Shyr, Yu, additional, Bunn, Paul A., additional, Minna, John D., additional, and Hirsch, Fred R., additional

Published
2022
Full Text
View/download PDF

215. Breakthrough SARS-CoV-2 Infections Among Patients with Cancer Following Two and Three Doses of COVID-19 mRNA Vaccines

Author

Choueiri, Toni K., primary, Labaki, Chris, additional, Bakouny, Ziad, additional, Hsu, Chih-Yuan, additional, Schmidt, Andrew L., additional, de Lima Lopes, Gilberto, additional, Hwang, Clara, additional, Singh, Sunny R.K., additional, Jani, Chinmay, additional, Weissmann, Lisa B., additional, Griffiths, Elizabeth A., additional, Halabi, Susan, additional, Wu, Ulysses, additional, Berg, Stephanie, additional, O’Connor, Timothy E., additional, Wise-Draper, Trisha M., additional, Panagiotou, Orestis A., additional, Klein, Elizabeth J., additional, Joshi, Monika, additional, Dutra, Miriam Santos, additional, Gatson, Na Tosha N., additional, Blau, Sibel, additional, Singh, Harpreet, additional, Nanchal, Rahul, additional, McKay, Rana R., additional, Nonato, Taylor K., additional, Quinn, Ryann, additional, Rubinstein, Samuel M., additional, Puc, Matthew, additional, Mavromatis, Blanche H., additional, Vikas, Praveen, additional, Faller, Bryan, additional, Zaren, Howard A., additional, Del Prete, Salvatore, additional, Russell, Karen, additional, Reuben, Daniel Y., additional, Accordino, Melissa, additional, Friese, Christopher R., additional, Mishra, Sanjay, additional, Rivera, Donna R., additional, Shyr, Yu, additional, Farmakiotis, Dimitrios, additional, and Warner, Jeremy L., additional

Published
2022
Full Text
View/download PDF

219. The CoVID-TE risk assessment model for venous thromboembolism in hospitalized patients with cancer and COVID-19

Author

Li, Ang, Kuderer, Nicole M, Hsu, Chih-Yuan, Shyr, Yu, Warner, Jeremy L, Shah, Dimpy P, Kumar, Vaibhav, Shah, Surbhi, Kulkarni, Amit A, Fu, Julie, Gulati, Shuchi, Zon, Rebecca L, Li, Monica, Desai, Aakash, Egan, Pamela C, Bakouny, Ziad, Kc, Devendra, Hwang, Clara, Akpan, Imo J, McKay, Rana R, Girard, Jennifer, Schmidt, Andrew L, Halmos, Balazs, Thompson, Michael A, Patel, Jaymin M, Pennell, Nathan A, Peters, Solange, Elshoury, Amro, de Lima Lopes, Gilbero, Stover, Daniel G, Grivas, Petros, Rini, Brian I, Painter, Corrie A, Mishra, Sanjay, Connors, Jean M, Lyman, Gary H, Rosovsky, Rachel P, and CCC19 consortium

Subjects
CCC19 consortium, SARS-CoV-2, Prevention, clinical decision rules, venous thromboembolism, Clinical Sciences, COVID-19, Hematology, Cardiorespiratory Medicine and Haematology, Risk Assessment, Cohort Studies, Cardiovascular System & Hematology, Clinical Research, Neoplasms, Humans, thrombosis, Cancer
Abstract

BackgroundHospitalized patients with COVID-19have increased risks of venous (VTE) and arterial thromboembolism (ATE). Active cancer diagnosis and treatment are well-known risk factors; however, a risk assessment model (RAM) for VTE in patients with both cancer and COVID-19 is lacking.ObjectivesTo assess the incidence of and risk factors for thrombosis in hospitalized patients with cancer and COVID-19.MethodsAmong patients with cancer in the COVID-19 and Cancer Consortium registry (CCC19) cohort study, we assessed the incidence of VTE and ATE within 90days of COVID-19-associated hospitalization. A multivariable logistic regression model specifically for VTE was built using a priori determined clinical risk factors. A simplified RAM was derived and internally validated using bootstrap.ResultsFrom March 17, 2020 to November 30, 2020, 2804hospitalized patients were analyzed. The incidence of VTE and ATE was 7.6% and 3.9%, respectively. The incidence of VTE, but not ATE, was higher in patients receiving recent anti-cancer therapy. A simplified RAM for VTE was derived and named CoVID-TE (Cancer subtype high to very-high risk by original Khorana score +1, VTE history +2, ICU admission +2, D-dimer elevation +1, recent systemic anti-cancer Therapy +1, and non-Hispanic Ethnicity +1). The RAM stratified patients into two cohorts (low-risk, 0-2 points, n=1423 vs. high-risk, 3+ points, n=1034) where VTE occurred in 4.1% low-risk and 11.3% high-risk patients (c statistic 0.67, 95% confidence interval 0.63-0.71). The RAM performed similarly well in subgroups of patients not on anticoagulant prior to admission and moderately ill patients not requiring direct ICU admission.ConclusionsHospitalized patients with cancer and COVID-19have elevated thrombotic risks. The CoVID-TE RAM for VTE prediction may help real-time data-driven decisions in this vulnerable population.

Published
2021

226. The CoVID‐TE risk assessment model for venous thromboembolism in hospitalized patients with cancer and COVID‐19

Author

Li, Ang, primary, Kuderer, Nicole M., additional, Hsu, Chih‐Yuan, additional, Shyr, Yu, additional, Warner, Jeremy L., additional, Shah, Dimpy P., additional, Kumar, Vaibhav, additional, Shah, Surbhi, additional, Kulkarni, Amit A., additional, Fu, Julie, additional, Gulati, Shuchi, additional, Zon, Rebecca L., additional, Li, Monica, additional, Desai, Aakash, additional, Egan, Pamela C., additional, Bakouny, Ziad, additional, KC, Devendra, additional, Hwang, Clara, additional, Akpan, Imo J., additional, McKay, Rana R., additional, Girard, Jennifer, additional, Schmidt, Andrew L., additional, Halmos, Balazs, additional, Thompson, Michael A., additional, Patel, Jaymin M., additional, Pennell, Nathan A., additional, Peters, Solange, additional, Elshoury, Amro, additional, de Lima Lopes, Gilbero, additional, Stover, Daniel G., additional, Grivas, Petros, additional, Rini, Brian I., additional, Painter, Corrie A., additional, Mishra, Sanjay, additional, Connors, Jean M., additional, Lyman, Gary H., additional, and Rosovsky, Rachel P., additional

Published
2021
Full Text
View/download PDF

236. A Grant-Based Experiment to Train Clinical Investigators: The AACR/ASCO Methods in Clinical Cancer Research Workshop

Author

Von Hoff, Daniel D., primary, Clark, Gary M., additional, Coltman, Charles A., additional, Disis, Mary L., additional, Eckhardt, S.G., additional, Ellis, Lee M., additional, Foti, Margaret, additional, Garrett-Mayer, Elizabeth, additional, Gönen, Mithat, additional, Hidalgo, Manuel, additional, Hilsenbeck, Susan G., additional, Littlefield, John H., additional, LoRusso, Patricia M., additional, Lyerly, H. Kim, additional, Meropol, Neal J., additional, Patel, Jyoti D., additional, Piantadosi, Steven, additional, Post, Dean A., additional, Regan, Meredith M., additional, Shyr, Yu, additional, Tempero, Margaret A., additional, Tepper, Joel E., additional, Von Roenn, Jamie, additional, Weiner, Louis M., additional, Young, Donn C., additional, and Vu, Nu V., additional

Published
2021
Full Text
View/download PDF

238. Interplay of Immunosuppression and Immunotherapy Among Patients With Cancer and COVID-19

Author

Bakouny, Ziad, Labaki, Chris, Grover, Punita, Awosika, Joy, Gulati, Shuchi, Hsu, Chih-Yuan, Alimohamed, Saif I., Bashir, Babar, Berg, Stephanie, Bilen, Mehmet A., Bowles, Daniel, Castellano, Cecilia, Desai, Aakash, Elkrief, Arielle, Eton, Omar E., Fecher, Leslie A., Flora, Daniel, Galsky, Matthew D., Gatti-Mays, Margaret E., Gesenhues, Alicia, Glover, Michael J., Gopalakrishnan, Dharmesh, Gupta, Shilpa, Halfdanarson, Thorvardur R., Hayes-Lattin, Brandon, Hendawi, Mohamed, Hsu, Emily, Hwang, Clara, Jandarov, Roman, Jani, Chinmay, Johnson, Douglas B., Joshi, Monika, Khan, Hina, Khan, Shaheer A., Knox, Natalie, Koshkin, Vadim S., Kulkarni, Amit A., Kwon, Daniel H., Matar, Sara, McKay, Rana R., Mishra, Sanjay, Moria, Feras A., Nizam, Amanda, Nock, Nora L., Nonato, Taylor K., Panasci, Justin, Pomerantz, Lauren, Portuguese, Andrew J., Provenzano, Destie, Puc, Matthew, Rao, Yuan J., Rhodes, Terence D., Riely, Gregory J., Ripp, Jacob J., Rivera, Andrea V., Ruiz-Garcia, Erika, Schmidt, Andrew L., Schoenfeld, Adam J., Schwartz, Gary K., Shah, Sumit A., Shaya, Justin, Subbiah, Suki, Tachiki, Lisa M., Tucker, Matthew D., Valdez-Reyes, Melissa, Weissmann, Lisa B., Wotman, Michael T., Wulff-Burchfield, Elizabeth M., Xie, Zhuoer, Yang, Yuanchu James, Thompson, Michael A., Shah, Dimpy P., Warner, Jeremy L., Shyr, Yu, Choueiri, Toni K., and Wise-Draper, Trisha M.

Abstract

IMPORTANCE: Cytokine storm due to COVID-19 can cause high morbidity and mortality and may be more common in patients with cancer treated with immunotherapy (IO) due to immune system activation. OBJECTIVE: To determine the association of baseline immunosuppression and/or IO-based therapies with COVID-19 severity and cytokine storm in patients with cancer. DESIGN, SETTING, AND PARTICIPANTS: This registry-based retrospective cohort study included 12 046 patients reported to the COVID-19 and Cancer Consortium (CCC19) registry from March 2020 to May 2022. The CCC19 registry is a centralized international multi-institutional registry of patients with COVID-19 with a current or past diagnosis of cancer. Records analyzed included patients with active or previous cancer who had a laboratory-confirmed infection with SARS-CoV-2 by polymerase chain reaction and/or serologic findings. EXPOSURES: Immunosuppression due to therapy; systemic anticancer therapy (IO or non-IO). MAIN OUTCOMES AND MEASURES: The primary outcome was a 5-level ordinal scale of COVID-19 severity: no complications; hospitalized without requiring oxygen; hospitalized and required oxygen; intensive care unit admission and/or mechanical ventilation; death. The secondary outcome was the occurrence of cytokine storm. RESULTS: The median age of the entire cohort was 65 years (interquartile range [IQR], 54-74) years and 6359 patients were female (52.8%) and 6598 (54.8%) were non-Hispanic White. A total of 599 (5.0%) patients received IO, whereas 4327 (35.9%) received non-IO systemic anticancer therapies, and 7120 (59.1%) did not receive any antineoplastic regimen within 3 months prior to COVID-19 diagnosis. Although no difference in COVID-19 severity and cytokine storm was found in the IO group compared with the untreated group in the total cohort (adjusted odds ratio [aOR], 0.80; 95% CI, 0.56-1.13, and aOR, 0.89; 95% CI, 0.41-1.93, respectively), patients with baseline immunosuppression treated with IO (vs untreated) had worse COVID-19 severity and cytokine storm (aOR, 3.33; 95% CI, 1.38-8.01, and aOR, 4.41; 95% CI, 1.71-11.38, respectively). Patients with immunosuppression receiving non-IO therapies (vs untreated) also had worse COVID-19 severity (aOR, 1.79; 95% CI, 1.36-2.35) and cytokine storm (aOR, 2.32; 95% CI, 1.42-3.79). CONCLUSIONS AND RELEVANCE: This cohort study found that in patients with cancer and COVID-19, administration of systemic anticancer therapies, especially IO, in the context of baseline immunosuppression was associated with severe clinical outcomes and the development of cytokine storm. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04354701

Published
2023
Full Text
View/download PDF

246. sj-pdf-1-aor-10.1177_0003489421995283 – Supplemental material for Association of Social Determinants of Health with Time to Diagnosis and Treatment Outcomes in Idiopathic Subglottic Stenosis

Author

Lee, Jaclyn, Li-Ching Huang, Berry, Lynn D., Anderson, Catherine, Amin, Milan R., Benninger, Michael S., Blumin, Joel H., Bock, Jonathan M., Bryson, Paul C., Castellanos, Paul F., Sheau-Chiann Chen, Clary, Matthew S., Cohen, Seth M., Crawley, Brianna K., Dailey, Seth H., Daniero, James J., Alarcon, Alessandro De., Donovan, Donald T., Edell, Eric S., Ekbom, Dale C., Fink, Daniel S., Franco, Ramon A., C. Gaelyn Garrett, Guardiani, Elizabeth A., Hillel, Alexander T., Hoffman, Henry T., Hogikyan, Norman D., Howell, Rebecca J., Hussain, Lena K., Johns, Michael M., Kasperbauer, Jan L., Khosla, Sid M., Kinnard, Cheryl, Kupfer, Robbi A., Langerman, Alexander J., Lentz, Robert J., Lorenz, Robert R., Lott, David G., Lowery, Anne S., Makani, Samir S., Maldonado, Fabien, Mannion, Kyle, Matrka, Laura, McWhorter, Andrew J., Merati, Albert L., Mori, Matthew, Netterville, James L., O’Dell, Karla, Ongkasuwan, Julina, Postma, Gregory N., Reder, Lindsay S., Rohde, Sarah L., Richardson, Brent E., Rickman, Otis B., Rosen, Clark A., Rutter, Michael J., Sandhu, Guri S., Schindler, Joshua S., G. Todd Schneider, Rupali N. Shah, Sikora, Andrew G., Sinard, Robert J., Smith, Marshall E., Smith, Libby J., Soliman, Ahmed M.S., Sveinsdóttir, Sigríður, Daele, Douglas J. Van, Veivers, David, Verma, Sunil P., Weinberger, Paul M., Weissbrod, Philip A., Wootten, Christopher T., Shyr, Yu, Francis, David O., and Gelbard, Alexander

Subjects
110315 Otorhinolaryngology, FOS: Clinical medicine
Abstract

Supplemental material, sj-pdf-1-aor-10.1177_0003489421995283 for Association of Social Determinants of Health with Time to Diagnosis and Treatment Outcomes in Idiopathic Subglottic Stenosis by Jaclyn Lee, Li-Ching Huang, Lynn D. Berry, Catherine Anderson, Milan R. Amin, Michael S. Benninger, Joel H. Blumin, Jonathan M. Bock, Paul C. Bryson, Paul F. Castellanos, Sheau-Chiann Chen, Matthew S. Clary, Seth M. Cohen, Brianna K. Crawley, Seth H. Dailey, James J. Daniero, Alessandro de. Alarcon, Donald T. Donovan, Eric S. Edell, Dale C. Ekbom, Daniel S. Fink, Ramon A. Franco, C. Gaelyn Garrett, Elizabeth A. Guardiani, Alexander T. Hillel, Henry T. Hoffman, Norman D. Hogikyan, Rebecca J. Howell, Lena K. Hussain, Michael M. Johns, Jan L. Kasperbauer, Sid M. Khosla, Cheryl Kinnard, Robbi A. Kupfer, Alexander J. Langerman, Robert J. Lentz, Robert R. Lorenz, David G. Lott, Anne S. Lowery, Samir S. Makani, Fabien Maldonado, Kyle Mannion, Laura Matrka, Andrew J. McWhorter, Albert L. Merati, Matthew Mori, James L. Netterville, Karla O’Dell, Julina Ongkasuwan, Gregory N. Postma, Lindsay S. Reder, Sarah L. Rohde, Brent E. Richardson, Otis B. Rickman, Clark A. Rosen, Michael J. Rutter, Guri S. Sandhu, Joshua S. Schindler, G. Todd Schneider, Rupali N. Shah, Andrew G. Sikora, Robert J. Sinard, Marshall E. Smith, Libby J. Smith, Ahmed M.S. Soliman, Sigríður Sveinsdóttir, Douglas J. Van Daele, David Veivers, Mepi FRACS, Sunil P. Verma, Paul M. Weinberger, Philip A. Weissbrod, Christopher T. Wootten, Yu Shyr, David O. Francis and Alexander Gelbard in Annals of Otology, Rhinology & Laryngology

Published
2021
Full Text
View/download PDF

248. Analysis of homologous recombination DNA repair gene mutation status in patients with metastatic small cell lung cancer treated with cediranib and olaparib on NCI 9881 study.

Author

Kim, Joseph W., primary, Radke, Marc R., additional, Hafez, Navid, additional, Soliman, Hatem Hussein, additional, Fu, Siqing, additional, Kato, Shumei, additional, Lara, Primo "Lucky" N., additional, Vaishampayan, Ulka N., additional, Abdul Razak, Albiruni Ryan, additional, Cardin, Dana Backlund, additional, Munster, Pamela N., additional, Eder, Joseph Paul, additional, Shyr, Yu, additional, Ivy, S. Percy, additional, LoRusso, Patricia, additional, and Swisher, Elizabeth M., additional

Published
2021
Full Text
View/download PDF

249. Phase I/II study of nivolumab plus vorolanib in patients with thoracic malignancies: Interim efficacy of the SCLC and primary refractory NSCLC cohorts, and safety data across all cohorts.

Author

Wong, Selina K., primary, Whisenant, Jennifer G., additional, Bestvina, Christine M., additional, Berry, Lynne D, additional, Owonikoko, Taofeek K., additional, Sanborn, Rachel E., additional, Lammers, Philip Edward, additional, El Osta, Badi Edmond, additional, Ramalingam, Suresh S., additional, Carlisle, Jennifer W, additional, Steuer, Conor Ernst, additional, Borghaei, Hossein, additional, Selvaggi, Giovanni, additional, Shyr, Yu, additional, Wakelee, Heather A., additional, Horn, Leora, additional, and Beckermann, Katy, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results